香菇多糖联合化疗对晚期结肠癌患者的临床疗效  

Clinical effect of Lentinan combined with chemotherapy for patients with advanced colon cancer

作　　者：王小红[1] 余新民[1] 沈祝苹[1] 罗聪[1] 

机构地区：[1]浙江省肿瘤医院化疗科,浙江杭州310022

出　　处：《中国医药导报》2014年第17期65-69,共5页China Medical Herald

基　　金：浙江省医药卫生一般研究计划项目A类(编号2013KYA023;2012KYA027)

摘　　要：目的探讨香菇多糖联合XELOX方案治疗晚期结肠癌的效果，以及香菇多糖在结肠癌治疗过程中的应用价值。方法将2008年1月～2009年12月浙江省肿瘤医院收治的124例晚期结肠癌患者分为两组，治疗组63例患者采用XELOX方案化疗的同时给予香菇多糖，对照组61例仅采用XELOX方案化疗。在化疗过程中比较两组患者的不良反应、生活质量评定，全部病例在完成4个周期治疗后作疗效评价，同时检测患者的T细胞免疫功能。随访6—60个月。比较两组患者的无进展生存期和总生存期。结果两组均未发生治疗相关性死亡。两组不良反应以血液学毒性、消化道反应、神经毒性为主，治疗组骨髓抑制发生率为77．8％（49／63），相比对照组的91．8％（56／61）显著性降低（P=0．030）；神经系统损害发生率分别为20．66％（13／63）和44．26％（27／61），差异有统计学意义（P=0．005）。治疗组KPS评分有效率为82．5％（52／63），而对照组有效率为41．0％（25／61），差异有高度统计学意义（χ2=22．738，P〈0．01）。化疗后治疗组的CD3、CD4和CD4／CD8均高于对照组。治疗组有效率为55．56％（35／63），高于对照组的31．15％（19／61）（χ2=7．510，P=0．006）。治疗组和对照组的临床有效率分别为79．37％（50／63）和62．29％（38／61）（χ2=4．383，P=0．036）。两组无进展生存率和生存率比较差异均无统计学意义（P=0．316、0．634）。结论香菇多糖联合XELOX方案化疗可增强患者的细胞免疫功能，提高化疗疗效，减轻化疗所致的毒副作用，明显改善生活质量，但其是否可以改善肿瘤患者的远期生存，尚待进一步研究。Objective To investigate the effect of Lentinan combined with XELOX in patients with advanced colon can- cer, to explore the value of Lentinan on treatment for colon cancer. Methods From January 2008 to December 2009 one hundred-four patients with advanced colon cancer in Zhejiang Cancer Hospital were divided into two groups. XELOX chemotherapy combined with Lentinan was administered to the treatment group （n=63）, and the control group received XELOX chemotherapy only （n=61）. Adverse reactions in the course of chemotherapy were compared, and quality of life was assessmented. All patients completed four cycles of therapy, then the efficacy was evaluated, T cell immune function in patients was detected. Followed up 6-60 months, progression-free survival （PFS） and overall sur- vival （OS） between two groups were compared. Results The treatment-related deaths did not occur in two groups. The common adverse reactions were hematologic toxicity, gastrointestinal toxicity, neurotoxicity in two groups. The occur- rence rate of bone marrow suppression was 77.8% （49/63） in treatment group, and 91.8% in control group, with a sig- nificant difference （P = 0.030）. The rate of nervous system damage was 20.66% （13/63） in treatment group and 44.26% （27/61） in control group, with a significant difference （P = 0.005）. The rate of KPS score improved was 82.5% （52/63） in treatment group, and 41.0% （25/61） in control group, with a significant difference （χ2=22.738, P 〈 0.01）. The short- term effect of patients in treatment group was better than that in control group （55.56% vs 31.15%, χ2=7.510, P = 0.006）. Clinical efficiency in treatment group was better than that in control group （79.37% vs 62.29%, χ2=4.383, P = 0.036）. The PFS and OS between two groups were not significantly different （P = 0.316, 0.634）. Conclusion Lentinan combined XELOX regimen can enhance cellular immune function in patients with colon cancer, and improve the effi- cacy of chemotherapy, reduce the s

关 键 词：香菇多糖 结肠癌 化疗 

分 类 号：R735.35[医药卫生—肿瘤]